文献速递脑血管病神经重症与神经感染

CLEAR III 试验中的脑室内出血扩大:一项事后探索性分析

Intraventricular Hemorrhage Expansion in the CLEAR III Trial: A Post Hoc Exploratory Analysis.
PubMed 文献 · Stroke · 2022-01-28

本研究为国际多中心 CLEAR III 试验的事后分析,纳入 2009 年 9 月 1 日至 2015 年 1 月 31 日间 500 例脑室内出血患者。结果显示 135 例(27%)出现脑室内出血扩大,基线脑实质出血体积、血肿扩大>33%、稳定头颅 CT 时间及丘脑出血位置与脑室内出血扩大相关;脑室内出血扩大与 6 个月不良结局相关(校正 OR 1.84),但与死亡率及脑室腹腔分流置入无显著关联。

要点

  • 500 例脑室内出血患者中 135 例(27%)出现脑室内出血扩大。
  • 基线脑实质出血体积每增加 1 mL,脑室内出血扩大校正 OR 为 1.04(95%CI 1.01-1.08)。
  • 脑室内出血扩大与 6 个月死亡或重度残疾复合结局相关(校正 OR 1.84,95%CI 1.12-3.02)。

核心结论

  • 在大规模脑室内出血临床试验队列中,急性血肿特征(较大的脑实质出血体积、血肿扩大及丘脑出血位置)与脑室内出血扩大相关。
  • 脑室内出血扩大导致功能结局不良,探索优化止血和预防脑室内出血扩大的治疗方法(尤其丘脑出血患者)需进一步研究。

研究设计与样本

  • 国际多中心 CLEAR III 试验( clot 溶解:评估加速脑室内出血溶解)的事后探索性分析,纳入 2009 年 9 月 1 日至 2015 年 1 月 31 日间脑室内出血患者。
  • 共分析 500 例脑室内出血患者,平均年龄 59(±11)岁,44% 为女性。
  • 暴露为脑室内出血扩大,定义为基线至稳定头颅 CT 扫描之间体积增加>1 mL,且发生在治疗随机化之前。
  • 采用多变量 logistic 回归分析。

主要发现

  • 135 例(27%)出现脑室内出血扩大。
  • 与脑室内出血扩大相关的因素:基线脑实质出血体积(校正 OR 1.04,每增加 1 mL,95%CI 1.01-1.08)、脑实质血肿扩大>33%(校正 OR 6.63,95%CI 3.92-11.24)、稳定头颅 CT 时间(校正 OR 0.71,每增加 1 小时,95%CI 0.54-0.94)、丘脑出血位置(校正 OR 1.68,95%CI 1.01-2.79),并额外调整年龄、性别和种族。
  • 脑室内出血扩大与 6 个月不良结局(死亡或重度残疾复合,改良 Rankin 量表评分>3)相关(校正 OR 1.84,95%CI 1.12-3.02),但与死亡率无关(OR 1.40,95%CI 0.78-2.50),调整基线脑实质出血体积、丘脑出血位置、年龄、抗凝药使用、格拉斯哥昏迷量表评分、任何放弃治疗医嘱及治疗随机化分组。
  • 脑室内出血扩大与后续脑室腹腔分流置入无关(校正 OR 1.02,95%CI 0.58-1.80),调整相似协变量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of this study was to evaluate factors associated with intraventricular hemorrhage (IVH) expansion and its association with long-term outcomes. METHODS: We performed a post hoc analysis of the international, multi-center CLEAR III trial (Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage) which enrolled IVH patients between September 1, 2009, and January 31, 2015. The exposure was IVH expansion, defined as >1 mL increase in volume between baseline and stability computed tomography scans, before treatment randomization. We assessed factors associated with IVH expansion and secondarily assessed the relationship of IVH expansion with clinical outcomes: composite of death or major disability (modified Rankin Scale score, >3), and mortality alone at 6 months. The relationship of IVH expansion on ventriculoperitoneal shunt placement was additionally explored. Multivariable logistic regression was used for all analyses. RESULTS: Of 500 IVH patients analyzed, the mean age was 59 (±11) years old, 44% were female and 135 (27%) had IVH expansion. In multivariable regression models, factors associated with IVH expansion were baseline parenchymal intracerebral hemorrhage (ICH) volume (adjusted odds ratio [OR], 1.04 per 1 mL increase [95% CI, 1.01-1.08]), presence of parenchymal hematoma expansion: >33% (adjusted OR, 6.63 [95% CI, 3.92-11.24]), time to stability head CT (adjusted OR, 0.71 per 1 hour increase [95% CI, 0.54-0.94]), and thalamic hematoma location (adjusted OR, 1.68 [95% CI, 1.01-2.79]) while additionally adjusting for age, sex, and race. In secondary analyses, IVH expansion was associated with higher odds of poor 6-month outcomes (adjusted OR, 1.84 [95% CI, 1.12-3.02]) but not mortality (OR, 1.40 [95% CI, 0.78-2.50]) after adjusting for baseline ICH volume, thalamic ICH location, age, anticoagulant use, Glasgow Coma Scale score, any withdrawal of care order, and treatment randomization arm. However, there were no relationships of IVH expansion on subsequent ventriculoperitoneal shunt placement (adjusted OR, 1.02 [95% CI, 0.58-1.80]) after adjusting for similar covariates. CONCLUSIONS: In a clinical trial cohort of patients with large IVH, acute hematoma characteristics, specifically larger parenchymal volume, hematoma expansion, and thalamic ICH location were associated with IVH expansion. Given that IVH expansion resulted in poor functional outcomes, exploration of treatment approaches to optimize hemostasis and prevent IVH expansion, particularly in patients with thalamic ICH, require further study. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT00784134.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Roh DJ, Asonye IS, Carvalho Poyraz F, et al. Intraventricular Hemorrhage Expansion in the CLEAR III Trial: A Post Hoc Exploratory Analysis. Stroke. 2022. PMID: 35086362. doi:10.1161/STROKEAHA.121.037438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。